Teduglutide News
Teduglutide currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Teduglutide with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery....
- Evidence level: L5
- Predicted indications (20):
- short bowel syndrome (99.1%)
- papillary conjunctivitis (98.5%)
- gastroduodenitis (98.2%)
- peptic ulcer disease (96.6%)
- nasal cavity disease (96.2%)
- acute laryngopharyngitis (95.2%)
- allergic urticaria (95.2%)
- pharyngitis (94.7%)
- chronic intestinal vascular insufficiency (92.2%)
- isolated mesenteric vein thrombosis (92.0%)
- atopic conjunctivitis (88.7%)
- cold urticaria (87.9%)
- rosacea conjunctivitis (87.5%)
- ischemic bowel disease (87.5%)
- NK-cell enteropathy (86.5%)
- eosinophilic gastrointestinal disease (86.5%)
- intestinal atresia (disease) (86.4%)
- solitary rectal ulcer syndrome (86.3%)
- neurogenic bowel (86.3%)
- mucocele of appendix (86.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.